High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. (Q48326616)

10 February 2018

title

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. (English)

1 reference

10 February 2018

0 references

1 reference

chronic heart failure

1 reference

inferred from title

author

Harry J. G. M. Crijns

9

object named as

Crijns HJ

1 reference

10 February 2018

Kong I. Lie

8

object named as

Lie KI

1 reference

10 February 2018

author name string

van Veldhuisen DJ

1

1 reference

10 February 2018

Genth-Zotz S

2

1 reference

10 February 2018

Brouwer J

3

1 reference

10 February 2018

Boomsma F

4

1 reference

10 February 2018

Netzer T

5

1 reference

10 February 2018

Man In 'T Veld AJ

6

1 reference

10 February 2018

Pinto YM

7

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 December 1998

1 reference

10 February 2018

Journal of the American College of Cardiology

published in

1 reference

10 February 2018

volume

32

1 reference

10 February 2018

issue

7

1 reference

10 February 2018

page(s)

1811-1818

1 reference

10 February 2018

The management of chronic heart failure

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

ACE inhibitors for heart failure: a question of dose

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Dose finding studies with imidapril--a new ACE inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Arterial elasticity and physical working capacity in young men.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Chronotropic response to exercise in patients with atrial fibrillation: relation to functional state

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Increased plasma concentrations of endothelin in congestive heart failure in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Stability of human plasma atrial natriuretic peptide during storage at -80 degrees C

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Physiological parameters during the initial stages of cardiopulmonary exercise testing in patients with chronic heart failure. Their value in the assessment of clinical severity and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Relative attenuation of sympathetic drive during exercise in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Interruption of the progression of heart failure: are ACE inhibitors the solution?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Differential Inhibition of Plasma Versus Tissue ACE by Utibapril: Biochemical and Functional Evidence for Inhibition of Vascular ACE Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Effect of beta adrenergic blockade on renin response to renal nerve stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Tissue angiotensin system in cardiovascular medicine. A paradigm shift?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900464-1

7 January 2021

10.1016/S0735-1097(98)00464-1

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

9857856

1 reference

10 February 2018